2nd ANNUAL GBM SUMMIT 8 - 10th DEC, page-4

Yes Gofish1.....I agree now, its not much of an exclusive, if the document was dated Dec 19.

I recall at the initial GBM Annual Event (which was in Dec 2019).....Genentech was listed to do a GDC 0084 presentation. We never saw the actual content of that Dec 19 presentation - but looks like, this is it. Why are they giving it another run and calling it exclusive content presentation ? .......Anyway even 12 months late, it is off interest that Genentech, would assemble this information.

----------------

This 2nd event goes for three days, with many different drugs and approaches to tackle GBM.

The KZA CEO now most definitely talking about Paxalisib  in combo....... we need to increase OS, with a two or three drug treatment regime now. Paxalisib  (a PI3K Pan Inhibitor) is tasked to repair damaged pathways that carry cancer enzymes. Returning this pathway to normal function, means other drugs can work better. Additional drugs and strategies discussed, only compliment PI3k pathway inhibitors in the fight against cancers, in combination.

More specific pathway drugs are under development - upstream of the PI3 pathway.  

Priscilla Brastanous (highly regarded young Harvard Investigator) makes specific reference to the PI3k pathway, as being like the neck of Hydra (the 9 headed Greek monster).........attack the neck of Hydra (aka PI3k Pathway)  and kill the monster (cancer). Priscilla analogy----------------------------------------
Aust investors looking for data now - but I don't know if that is the case in the US. Still worth posting -  social postings chatlines work, and can work to get message out there. But it does see like flogging a dead horse, at the moment.

Priscilla Brasanious undertaking a trial in brain Breast, Lung, Skin, Blood and Colorectal cancers (US Gov are paying for it)....and the company say this drug works outside the brain - if successful this is a top ten $35 b drug....watching grass grow is more interesting - lack of rain here, means its not growing.

-----------------------------------------------------------------------

One last thing.....this GBM Summit is hosted by a group called .... (Hanson Wade - who builds world leading conferences and data products in high growth industries. Learn about our strategy, our people and our story so far. More. Products. We are experts in creating and delivering conferences, data and bespoke events. Discover more about the sectors we serve.)

Hanson Wade also organized this summit - but it was cancelled due the virus.  A real shame..... I have done a cut and paste of all the presentations scheduled for this event. Nobody here is  going to read all this below -  but glance through who was to attend and how specific and relevant those cancelled presentations would have been. You wil be surprised.

This cancelled summit was far more high impact that the GBM meeting next week......potentially Paxalisib is the only PI3k drug that enters the brain and works in primary cancers. Some perspective on what we may have here - so if you wish, glance through who is talking bout PI3K and cancers, only last August
PI3K Pathways Digital Summit | Friday, August 28 | Home


Harnessing Metabolism for the Diagnosis and Treatment of Mutant PIK3CA-Bearing Cancers • The data presented here show how tracking the metabolic fingerprints of mutant PIK3CA-bearing breast cancers can offer a novel approach to diagnose and treat them using a “drug & diet” combination. • As we are able to unravel new evidence and understand more about the metabolism of cancer cells, using diet and nutrition to complement targeted drugs gets closer to becoming a reality. 10.00 / 5.00 Drugging the PI3K Pathway: Biological Insights from Comparative Pharmacology • Successful targeting of a driver oncoprotein should generate therapeutic benefit in oncogene-addicted tumours. However, only a fraction of tumours respond to targeted therapies • Although the reasons for these failures are manifold and include both tumour cell intrinsic and tumour cell extrinsic factors, sub-optimal pharmacology and an incomplete understanding of the target’s biology also contribute to unsuccessful therapies • AKT is a critical effector of the PI3K pathway and mediates many of its oncogenic activity. But, inhibitors of AKT have shown poor single agent activity • Using comparative pharmacology, we have uncovered kinaseindependent functions of AKT which should be considered when assessing therapeutic response and in new drug development efforts 10.20 / 5.20 New Insights into PI3K Dose Control and its Therapeutic Implications • Differences in mutant PI3Kα dose govern distinct biology and may influence therapeutic considerations in cancer • Transcriptionally-inferred PI3K activity scores have prognostic value in breast cancer and outperform binary genetic stratification according to PIK3CA mutant status • Indices of ’stemness’/dedifferentiation should be considered alongside growth and survival phenotypes when targeting tumours with high PI3K activity scores 10.40 / 5.40 Live Q&A – Ask the Speakers Your Burning Questions George Poulogiannis Team Leader, Signalling & Cancer Metabolism The Institute of Cancer Research Igor Vivanco Team Leader - Molecular Addictions Institute of Cancer Research Ralitsa Madsen Research Fellow University College London 11.00 / 6.00 Networking Break • Explore Demo Area and Virtual Booths • 1-1 Meetings 11.15 / 6.15 The Unexpected Function and Location of PIK3Cδ • Overall survival was markedly worse when levels of the protein PIK3Cδ were high in surrounding healthy tissue. • This presentation will share data to suggest that if treatments could control levels of PIK3Cδ in the surrounding normal cells, then survival outcomes for patients would improve. 11.35 / 6.35 Advancing SHIP Inhibitors as Potential Therapeutics • Modulating the activity of the Src Homology 2 (SH2)-containing Inositol 5 0-Phosphatase (SHIP) enzyme family with small molecule inhibitors provides a useful and unconventional method of influencing cell signaling in the PI3K pathway. • This presentation will discuss research that support targeting the SHIP1, SHIP2 or both enzymes for therapeutic purposes. Virtual Agenda: Friday, August 28 9AM-7.30PM GMT | 4AM - 2.30PM ET Igor Vivanco Team Leader - Molecular Addictions Institute of Cancer Research George Poulogiannis Team Leader, Signalling & Cancer Metabolism The Institute of Cancer Research William Kerr Cheif Scientific Officer Alterna Therapeutics Ralitsa Madsen Research Fellow University College London Teresa Gagliano Tenure-Track Assistant Professor University of Udine www.pi3k-pathways.com Email: [email protected] Tel: +1 617 455 4188 Virtual Agenda: Friday, August 28 11.55 / 6.55 Live Q&A – Ask the Speakers Your Burning Questions William Kerr Cheif Scientific Officer Alterna Therapeutics Teresa Gagliano Tenure-Track Assistant Professor University of Udine 12.10 / 7.10 Morning Networking • Explore Demo Area and Virtual Booths • 1-1 Meetings 12.10 / 7.10 Virtual Speed Networking • Recreating the face-to-face networking in the virtual world. We will pair you up with fellow attendees to break the ice and make new business relationships! Targeting the PI3K Pathway – Large Pharma Case Studies 12.50 / 7.50 Alternative Dosing Schemes of Pan-PI3K Inhibitors to Engage an Anti-Cancer Immune Response • Bayer’s Aliqopa is the only drug in its class to show inhibitory activity predominantly against PI3K-alpha and PI3K-delta isoforms expressed in malignant B cells. • This presentation will explore key lessons around immune modulation, dosing schedule, safety, and combination strategy. 1.10 / 8.10 A Gilead Case Study: bringing the first PI3K delta inhibitor to the market Gilead’s idelalisib (Zydelig) was the first PI3K delta inhibitor to gain approval from the FDA and EMA in selected hematological malignancies in 2014. We revisit the key clinical trial data leading to approval, use in the clinic along with lessons learnt, how the safety profile can be potentially optimized and some possible future directions. 1.30 / 8.30 A Genentech Case Study • Dysregulation of PI3K signaling is implicated in a broad range of human cancers and activating mutations in the PI3K alpha-isoform gene (PIK3CA) are common oncogenic drivers. • Sharing lessons learnt and key preclinical data. 1.50 / 8.50 A Novartis Case Study: PI3K in Breast Cancer • The FDA approval of Piqray, which was discovered at the Novartis Institutes for BioMedical Research, marks the first ever treatment specifically for HR+/HER2- advanced breast cancer with a PIK3CA mutation. • Sharing clinical data from key trials and how this will inform future research. 2.10 / 9.10 Live Q&A – Ask the Speakers Your Burning Questions Ningshu Liu Head of Laboratory Immuno Oncology & Senior Director & Global Strategy Lead Bayer Nishan Rajakumaraswamy Director, Clinical Research, Oncology/ Hematology Gilead Sciences Anwesha Dey Project Team Leader and Senior Scientist Genentech Cornelia Quadt Sr. Clinical Program Leader, Translational Clinical Oncology Novartis Nishan Rajakumaraswamy Director, Clinical Research, Oncology/ Hematology Gilead Sciences Anwesha Dey Project Team Leader and Senior Scientist Genentech Cornelia Quadt Sr. Clinical Program Leader, Translational Clinical Oncology Novartis 9AM-7.30PM GMT | 4AM - 2.30PM ET Ningshu Liu Head of Laboratory Immuno Oncology & Senior Director & Global Strategy Lead Bayer www.pi3k-pathways.com Email: [email protected] Tel: +1 617 455 4188 Virtual Agenda: Friday, August 28 2.30 / 9.30 Networking Break • Explore Demo Area and Virtual Booths • 1-1 Meetings Targeting the PI3K Pathway – Preclinical, Translational & Clinical Advances 2.50 / 9.50 Selective Targeting of PI3Kδ for the Treatment of Solid Tumours: Immune Mediated and Direct Anti-Cancer Activity • iOnctura is developing a PI3Kδ small molecule inhibitor which has just entered a phase I clinical trial in solid tumours. • This presentation will discuss key preclinical data for the molecule and explore how this will inform the clinical development plan. 3.10 / 10.10 Characterization of the Mechanism of Action and Efficacy of MEN1611, a Novel PI3K Inhibitor, in Breast Cancer Preclinical Models • About 25% of HER2-positive breast cancers also carry PIK3CA mutations, known to confer resistance to anti-HER2 therapy. • This presentation explores the preclinical characterization of MEN1611, a potent and selective orally available PI3K inhibitor, showing the strongest activity against the p110α isoform while sparing the δ isoform 3.30 / 10.30 PI3K Inhibitors for the Treatment of Venous and Lymphatic Malformations via Topical Formulations • Many cutaneous VMs and LMs are driven by mutations in PI3K or its upstream driver, TIE2. • Venthera are currently developing a topical PI3K inhibitor in order to safely and effectively treat these lesions at their source. 3.50 / 10.50 The Role of PI3Kd Inhibitors in B cell Malignancies • PI3Kδ is predominately expressed in leukocytes and has been found overexpressed in B-cell related malignancies such as CLL. • This presentation will share recent updates on PI3Kd inhibitors in B cell malignancies and explore correlative T cell findings from B cell malignancies trials, associated with toxicity. 4.10 / 11.10 Live Q&A – Ask the Speakers Your Burning Questions Zoe Johnson Chief Scientific Officer iOnctura Alessio Fiascarelli Research Scientist Menarini Group Thomas Rossi CEO Venthera Jennifer Brown Professor of Medicine at Harvard Medical School and Director of the CLL Center, DanaFarber Cancer Institute 4.20 / 11.30 Networking Break • Explore Demo Area and Virtual Booths • 1-1 Meetings 4.45 / 11.45 ROUND TABLE DISCUSSION: Isoforms Specific Agents vs Pan PI3K Inhibitors: Opportunities & Challenges Emmanuel Normant Vice President - Preclinical Sciences TG Therapeutics Christian Ottensmeier Professor - Experimental Cancer Medicine, University of Southampton Swaroop Vakkalanka President Rhizen Zoe Johnson Chief Scientific Officer iOnctura 9AM-7.30PM GMT | 4AM - 2.30PM ET Jennifer Brown Professor of Medicine at Harvard Medical School and Director of the CLL Center, DanaFarber Cancer Institute Zoe Johnson Chief Scientific Officer iOnctura Alessio Fiascarelli Research Scientist Menarini Group Thomas Rossi CEO Venthera www.pi3k-pathways.com Email: [email protected] Tel: +1 617 455 4188 Virtual Agenda: Friday, August 28 5.30 / 12.30 Developing a PI3K Inhibitor for Brain Cancer – What We Have Learned • Rationale for PI3K inhibitors in brain cancer and the challenge of the blood-brain barrier • Identification of optimal target populations and the significance of PI3K biomarkers • Perspectives on combination strategies and management of toxicities 5.50 / 12.50 Co-Targeting PIM Kinase and PI3K to Mitigate Acquired Resistance and Expand Therapeutic Spectrum of PI3K Inhibition • Initial in vitro efficacy with IBL-202 in a panel of cell lines was carried out showing it to be superior to PI3K or PIM kinase inhibition alone. In collaboration with research partners, pre-clinical efficacy with IBL202 has been demonstrated in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and multiple myeloma. • This presentation will discuss data to support co-targeting PIM Kinase and PI3K to mitigate resistance. 6.10 / 1.10 Targeting PI3K Pathway and Key resistance Mechanisms – Will We Improve Outcomes? • Cancer resistance to PI3K inhibitor therapy can be in part mediated by increases in PIM kinases as well as through the mTORC1/Mcl-1 pathway. • This presentation will discuss pre-clinical data around AUM302, a unique multi-targeted cancer therapeutic that targets not only PI3K, but also key resistance mechanisms such as PIM and mTOR. 6.30 / 1.30 Live Q&A – Ask the Speakers Your Burning Questions James Garner Chief Executive Officer & Managing Director Kazia therapeutics Murray Yule Chief Medical Officer Inflection Biosciences Harish Dave Co-Founder, Chief Medical Officer AUM Biosciences 6.50 / 1.50 Networking Break • Explore Demo Area and Virtual Booths • 1-1 Meetings 7.10 / 2.50 PANEL DISCUSSION: Making PI3K Inhibitors Work in the Clinic • Developing effective combination strategies • Targeting beyond the PI3K pathway • Disease specific resistance mechanisms • Isoform specific vs Pan PI3K inhibitors in mitigating resistance Moderator: Bart Vanhaesebroeck Professor - Cell Signalling University College London Kathy Gately Senior Lecturer – Clinical Trinity College Dublin Sathish Pad Scientist III University of Arizona Christian Ottensmeier Professor - Experimental Cancer Medicine University of Southampton Murray Yule Chief Medical Officer Inflection Biosciences 7.50 / 2.50 Close of Conference 9AM-7.30PM GMT | 4AM - 2.30PM ET James Garner Chief Executive Officer & Managing Director Kazia therapeutics Murray Yule Chief Medical Officer Inflection Biosciences Harish Dave Co-Founder, Chief Medical Officer AUM Biosciences www.pi3k-pathways.com Email: [email protected] Tel: +1 617 455 4188 Swaroop Vakkalanka President Rhizen Umbralsib and Tenalisib – Second generation PI3K delta and delta/ gamma inhibitors – therapeutic potential BONUS CONTENT We are proud to offer you a number of exclusive pre-recorded presentations which will be available to watch post-event. Our bonus content speaker will be